Incidence of Staphylococcus aureus with reduced susceptibility to glycopeptides in two French hospitals

• Published in: Clinical microbiology and infection Vol. 7; no. 5; pp. 267 - 272
• Main Authors: Reverdy, M.E., Jarraud, S., Bohin-Duhreux, S., Buret, E., Girardo, P., Lina, G., Vandenesch, F., Etienne, J.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Elsevier Ltd 01.05.2001; Blackwell Science Ltd; Blackwell
• Subjects: Anti-Bacterial Agents - pharmacology; Anti-Bacterial Agents - therapeutic use; Antibacterial agents; Antibiotics. Antiinfectious agents. Antiparasitic agents; Biological and medical sciences; Drug Resistance, Microbial; Drug Resistance, Multiple; Electrophoresis, Gel, Pulsed-Field; France - epidemiology; glycopeptides; Humans; Incidence; Medical sciences; Methicillin Resistance; Microbial Sensitivity Tests; Microscopy, Electron; Pharmacology. Drug treatments; resistance; Staphylococcal Infections - drug therapy; Staphylococcal Infections - epidemiology; Staphylococcal Infections - microbiology; Staphylococcus aureus; Staphylococcus aureus - drug effects; Staphylococcus aureus - isolation & purification; teicoplanin; Teicoplanin - pharmacology; Teicoplanin - therapeutic use; vancomycin; Vancomycin - pharmacology; Vancomycin - therapeutic use; Vancomycin Resistance; France; teicoplanin; vancomycin; glycopeptides; Staphylococcus aureus; resistance; Human; Peptides; Drug susceptibility test; Vancomycin; Epidemiology; Teicoplanin; Incidence; Glycopeptide; Minimum inhibitory concentration; Bacteria; Micrococcales; Micrococcaceae; Hospital; Antibacterial agent; Clinical isolate
• ISSN: 1198-743X; 1469-0691
• DOI: 10.1046/j.1198-743x.2001.00256.x

Objectives To determine the incidence of Staphylococcus aureus isolates with reduced susceptibility to glycopeptides among all clinical isolates collected consecutively in two French hospitals between November 1998 and April 1999. Methicillin-resistant and -susceptible S. aureus isolates were screened on vancomycin- or teicoplanin-supplemented agar plates. Glycopeptide MICs were determined by the E test procedure with a high inoculum and by an agar dilution technique. Glycopeptide-intermediate S. aureus isolates were identified as homogeneously or heterogeneously resistant to vancomycin by performing population analysis. Of the 640 isolates recovered from 518 patients, three from the same patient and two from two different patients showed homogeneous or heterogeneous intermediate resistance to vancomycin. The incidence of glycopeptide-intermediate S. aureus (homogeneously or heterogeneously resistant) in a non-selected patient population, i.e. regardless of predisposing factors and glycopeptide therapeutics, remains low in the two French hospitals involved in the study, representing 0.6% of isolates.